Amgen Shares Drop 0.66% After Six Consecutive Gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Stock Fluctuation: Amgen's shares fell 0.66% to $344.78 after a six-day gain of over 7.02%, indicating market caution regarding its short-term performance.
- Market Rating Change: Bernstein downgraded Amgen to Market Perform, projecting the stock to fluctuate within 15% of its $335 target for 2026, reflecting concerns about future growth.
- Analyst Perspectives: Despite conservative ratings, UBS upgraded Amgen to Buy, believing that its obesity drug MariTide and cardiovascular risk reduction drug olpasiran will drive growth through 2030, showcasing confidence in its pipeline.
- Investor Sentiment: Wall Street analysts are optimistic about Amgen, with 14 analysts rating it a Buy or higher, indicating market recognition of its future potential, despite 15 analysts maintaining Hold ratings.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 345.87 USD with a low forecast of 272.00 USD and a high forecast of 425.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
11 Buy
7 Hold
1 Sell
Moderate Buy
Current: 347.070
Low
272.00
Averages
345.87
High
425.00
Current: 347.070
Low
272.00
Averages
345.87
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
